Longitudinal association between internalized HIV stigma and antiretroviral therapy adherence for women living with HIV
Authors:
- Whitney S. RiceWhitney S. Rice
- Kaylee B. CrockettKCKaylee B. Crockett
- Mallory JohnsonMJMallory Johnson
- Torsten B. NeilandsTNTorsten B. Neilands
- Shericia N. RossSRShericia N. Ross
- Mirjam-Colette KempfMKMirjam-Colette Kempf
- Deborah Konkle-ParkerDKDeborah Konkle-Parker
- Gina WingoodGWGina Wingood
- Phyllis C. TienPTPhyllis C. Tien
- Mardge CohenMCMardge Cohen
- Tracey E. WilsonTWTracey E. Wilson
- 1 March 2019
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 33 (3) , 571-576
Abstract
We investigated whether internalized HIV-related stigma predicts adherence to antiretroviral therapy (ART) longitudinally in women living with HIV in the United States, and whether depression symptoms mediate the relationship between internalized stigma and suboptimal ART adherence. Observational longitudinal study utilizing data from the Women's Interagency HIV Study cohort. A measure of internalized HIV-related stigma was added to the battery of Women's Interagency HIV Study measures in 2013. For current analyses, participants’ first assessment of internalized HIV-related stigma and assessments of other variables at that time were used as baseline measures (Time one or T1, visit occurring in 2013/14), with outcomes measured approximately 2 years later (T3, 2015/16; n = 914). A measure of depression symptoms, assessed approximately 18 months after the baseline (T2, 2014/15), was used in mediation analyses (n = 862). Higher internalized HIV-related stigma at T1 predicted lower odds of optimal ART adherence at T3 (adjusted odds ratio = 0.61, P = 0.001, 95% confidence interval [0.45, 0.82]). Results were similar when ART adherence at T1 was added as a control variable. Mediation analysis revealed a significant indirect effect of internalized HIV stigma at T1 on ART adherence at T3 through depression symptoms at T2 (while controlling for depression symptoms and ART adherence at T1; B = −0.05, SE = 0.03, 95% confidence interval [−0.11, −0.006]). These results provide strong longitudinal support for the hypothesis that internalized HIV-related stigma results in suboptimal ART adherence in a large sample of women living with HIV in the United States, working through the pathway of increased depression symptoms.Keywords
This publication has 38 references indexed in Scilit:
- Racial/Ethnic Disparities in ART Adherence in the United StatesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: A randomized controlled trial.Journal of Consulting and Clinical Psychology, 2012
- A Structural Equation Model of HIV-Related Stigma, Depressive Symptoms, and Medication AdherenceAIDS and Behavior, 2011
- Longitudinal Relationships Between Antiretroviral Treatment Adherence and Discrimination Due to HIV-Serostatus, Race, and Sexual Orientation Among African–American Men with HIVAnnals of Behavioral Medicine, 2010
- The Association of Stigma with Self-Reported Access to Medical Care and Antiretroviral Therapy Adherence in Persons Living with HIV/AIDSJournal of General Internal Medicine, 2009
- HIV Stigma and Missed Medications in HIV-Positive People in Five African CountriesAIDS Patient Care and STDs, 2009
- A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals.Health Psychology, 2009
- The Role of Self-Efficacy in HIV Treatment Adherence: Validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES)Journal of Behavioral Medicine, 2007
- Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical ManagementAIDS and Behavior, 2006
- The CES-D ScaleApplied Psychological Measurement, 1977